BioNTech Valuation
| BNTX Stock | USD 117.39 3.17 2.78% |
At this time, the firm appears to be undervalued. BioNTech SE shows a prevailing Real Value of $132.85 per share. The current price of the firm is $117.39. Our model approximates the value of BioNTech SE from analyzing the firm fundamentals such as Current Valuation of 10.08 B, return on equity of -0.024, and Profit Margin of (0.15) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting BioNTech's valuation include:
Price Book 1.3632 | Enterprise Value 10.1 B | Enterprise Value Ebitda 110.8146 | Price Sales 9.0073 | Forward PE 7.0373 |
Undervalued
Today
Please note that BioNTech's price fluctuation is very steady at this time. Calculation of the real value of BioNTech SE is based on 3 months time horizon. Increasing BioNTech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since BioNTech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of BioNTech Stock. However, BioNTech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 117.39 | Real 132.85 | Target 151.1 | Hype 118.02 |
The intrinsic value of BioNTech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence BioNTech's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of BioNTech SE helps investors to forecast how BioNTech stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BioNTech more accurately as focusing exclusively on BioNTech's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use BioNTech's intrinsic value based on its ongoing forecasts of BioNTech's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against BioNTech's closest peers.
BioNTech Cash |
|
BioNTech Valuation Trend
Analysing the historical paterns of BioNTech's enterprise value and its market capitalization is a good way to estimate and gauge the value of BioNTech SE over time and is usually enough for investors to make rational market timing decisions.
BioNTech Total Value Analysis
BioNTech SE is currently anticipated to have valuation of 10.08 B with market capitalization of 27.38 B, debt of 219.1 M, and cash on hands of 9.33 B. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the BioNTech fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
10.08 B | 27.38 B | 219.1 M | 9.33 B |
BioNTech Investor Information
About 62.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.36. Some equities with similar Price to Book (P/B) outperform the market in the long run. BioNTech SE has Price/Earnings To Growth (PEG) ratio of 0.04. The entity recorded a loss per share of 1.93. The firm last dividend was issued on the 2nd of June 2022. BioNTech SE is doing better financially today then in previous quarter. It has a moderate odds of reporting better financial numbers in January.BioNTech Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. BioNTech has an asset utilization ratio of 16.6 percent. This suggests that the Company is making $0.17 for each dollar of assets. An increasing asset utilization means that BioNTech SE is more efficient with each dollar of assets it utilizes for everyday operations.BioNTech Ownership Allocation
BioNTech holds a total of 239.74 Million outstanding shares. BioNTech SE shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 61.65 percent of BioNTech SE outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. On October 4, 2024, Representative Josh Gottheimer of US Congress acquired under $15k worth of BioNTech SE's common stock.BioNTech Profitability Analysis
The company reported the previous year's revenue of 3.82 B. Net Income was 1.19 B with profit before overhead, payroll, taxes, and interest of 16.07 B.About BioNTech Valuation
Our relative valuation model uses a comparative analysis of BioNTech. We calculate exposure to BioNTech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of BioNTech's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 3.2 B | 4.8 B | |
| Pretax Profit Margin | 0.31 | 0.33 | |
| Operating Profit Margin | 0.18 | 0.19 | |
| Net Profit Margin | 0.24 | 0.26 | |
| Gross Profit Margin | 0.84 | 0.89 |
BioNTech Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 242.7 M | |
| Quarterly Earnings Growth Y O Y | 0.227 | |
| Forward Price Earnings | 7.0373 |
BioNTech Current Valuation Indicators
Valuation refers to the process of determining the present value of BioNTech SE and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value BioNTech we look at many different elements of the entity such as BioNTech's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as BioNTech, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use BioNTech's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes BioNTech's worth.Additional Tools for BioNTech Stock Analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.